

1 **Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite**  
2 **vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers**

3

4 Navin Venkatraman<sup>1^A&</sup>, Alfred B. Tiono<sup>2&</sup>, Georgina Bowyer<sup>1&</sup>, Jonathan Powlson<sup>1</sup>, Katharine  
5 A. Collins<sup>1</sup>, Sam Coulibaly<sup>2</sup>, Mehreen Dattoo<sup>1</sup>, Daniel Silman<sup>1</sup>, Alphonse Ouedraogo<sup>2</sup>, Issa  
6 Nébié<sup>2</sup>, Egeruan Imoukhuede<sup>1^A</sup>, Florian Brod<sup>1</sup>, Pedro Folegatti<sup>1</sup>, Emma Dickinson<sup>1</sup>, Sophie  
7 Jamieson<sup>1</sup>, Edith C. Bougouma<sup>2</sup>, Daniel Wright<sup>1</sup>, Duncan Bellamy<sup>1</sup>, Amidou Diarra<sup>2</sup>, Carly M.  
8 Bliss<sup>1</sup>, Richard Morter<sup>1</sup>, Greg Glenn<sup>4</sup>, Louis F. Fries<sup>4</sup>, Jenny Reimer<sup>5</sup> Karin Lövgren-  
9 Bengtsson<sup>5</sup> Megan Baker<sup>1</sup>, Ian Poulton<sup>1</sup>, Sarah Moyle<sup>3</sup>, Eleanor Berrie<sup>3</sup>, Nicola Green<sup>3</sup>, Ekta  
10 Mukhopadhyay<sup>3</sup>, Nicola Viebig<sup>6</sup>, Brian Angus<sup>7</sup>, Alison Lawrie<sup>1</sup>, Rachel Roberts<sup>1</sup>, Sarah C.  
11 Gilbert<sup>1</sup>, David J.M. Lewis<sup>8</sup>, Sodiomon B. Sirima<sup>2,9@</sup>, Katie J. Ewer<sup>1\*@</sup>, Adrian V. S. Hill<sup>1@</sup>.

12

13 <sup>1</sup>Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre,  
14 Oxford OX3 7DQ, UK.

15 <sup>2</sup>Centre National de Recherche et Formation sur le Paludisme (CNRFP) research unit,  
16 Banfora, Burkina Faso.

17 <sup>3</sup>Clinical Biomanufacturing Facility, University of Oxford, Churchill Hospital, Oxford, OX3 7JT.

18 <sup>4</sup>Novavax Inc, 20 Firstfield Road, Gaithersburg, MD 20878, USA.

19 <sup>5</sup>Novavax AB, Kungsgatan 109, SE-753 18 Uppsala, Sweden

20 <sup>6</sup>European Vaccine Initiative, UniversitätsKlinikum Heidelberg, Voßstr. 2, 69115, Germany

21 <sup>7</sup>Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford,  
22 OX3 9DU.

23 <sup>8</sup>NIHR Imperial Clinical Research Facility, Imperial Centre for Translational and Experimental  
24 Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.

25 <sup>9</sup> Current affiliation: Groupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina  
26 Faso.

27

28 <sup>^</sup> Deceased

29 <sup>@,&</sup> These authors contributed equally to this study.

30 *\*Corresponding author at:*

31 The Jenner Institute, Old Road Campus Research Building, University of Oxford, Headington,  
32 Oxford OX3 7DQ, United Kingdom.

33 *Telephone: +44 (0)1865 617622*

34 *Email: katie.ewer@ndm.ox.ac.uk*

35 Abstract: 250 words (limit 250)

36 Text (body): 4444 words (limit 4500)

37

38

39 **Keywords:** malaria, vaccine, circumsporozoite protein, Matrix-M

40

41

42

43

44

45

46

47

48 **ABSTRACT**

49 **Background** Improvements in malaria control have stalled recently and new tools are  
50 needed. The R21 vaccine is comprised of the malaria circumsporozoite protein fused to  
51 hepatitis B surface antigen (HBsAg). It forms particles that lack the excess HBsAg in the  
52 frequently tested malaria vaccine candidate, RTS,S/AS01<sub>B</sub>.

53 **Methods** We conducted an open-label, first-in-human, Phase Ia study evaluating safety and  
54 immunogenicity of R21 administered alone and with the saponin-based adjuvant, Matrix-  
55 M™ (MM). Twenty-eight healthy adults received three doses of R21 given intramuscularly 4  
56 weeks apart. We subsequently conducted a Phase Ib randomised, controlled trial in West  
57 African adults.

58 **Findings** Vaccinations were well tolerated, and the majority of local and systemic adverse  
59 events were mild. Reactogenicity was significantly lower in Burkina Faso than UK vaccinees  
60 ( $p < 0.0001$ ). Antibody responses increased significantly 28 days after the 2<sup>nd</sup> vaccination in  
61 UK volunteers. Antibody responses to R21 in all dose groups (2µg, 10µg and 50µg) were  
62 comparable to those of 50µg RTS,S/AS01<sub>B</sub> in malaria-naïve adults at 28 days after final  
63 vaccination. The 10µg dose induced more durable responses, with 2-fold higher NANP-  
64 specific IgG titres at 6 months compared with the 2µg and 50µg dose groups. R21 also  
65 boosted baseline humoral responses in Burkina Faso adults with well-maintained responses  
66 suggesting natural boosting.

67 **Interpretation** R21 adjuvanted with MM is safe and has comparable immunogenicity to  
68 RTS,S/AS01<sub>B</sub>, even when administered at a five-fold lower 10µg dose in UK and African  
69 populations. This forms the basis for efficacy testing of this vaccine which could prove to be  
70 particularly cost-effective to manufacture and deploy.

71

72 **INTRODUCTION**

73 Malaria remains one of the leading infectious causes of mortality worldwide and is caused  
74 by four species of the Plasmodium parasite in humans. *Plasmodium falciparum*  
75 predominantly affects children and pregnant women in sub-Saharan Africa and caused an  
76 estimated 219 million cases of malaria worldwide in 2017 (1). Increases in the distribution of  
77 long-lasting insecticidal nets (LLINs), widespread deployment of rapid diagnostic tests to  
78 target treatment with artemisinin-based combination therapy and use of intermittent  
79 preventive treatment in pregnant women have all contributed to a reduction in cases since  
80 2010 (2). However, progress has been highly variable, with 15 countries in sub-Saharan  
81 Africa and India experiencing nearly 80% of malaria cases and since 2016, cases have  
82 increased in the 10 African countries with the greatest disease burden (1). Recent advances  
83 in control interventions include seasonal malaria chemoprophylaxis (SMC) programs with  
84 nearly 16 million children receiving treatment in 2017 (3). The emergence and spread of  
85 resistance to artemisinins (4, 5) and insecticides (6), threatens malaria control efforts even  
86 further and so there remains an urgent need for a durable, efficacious malaria vaccine.

87 The most advanced malaria vaccine candidate, RTS,S/AS01<sub>B</sub>, designed in 1987, elicits  
88 antibodies to the pre-erythrocytic circumsporozoite protein (CSP) and has completed testing  
89 in a large Phase III clinical trial (7-10). The World Health Organisation's (WHO) Strategic  
90 Advisory Group of Experts (SAGE) on Immunization and the Malaria Policy Advisory  
91 Committee (MPAC), recommended further evaluation in a Malaria Vaccine Implementation  
92 Programme (MVIP), which has started in Malawi, Ghana and Kenya co-ordinated by WHO  
93 (11, 12). Though RTS,S has demonstrated significant vaccine efficacy of 46% in children after

94 three doses (7), this falls short of the goals set down by the Malaria Vaccine Technology  
95 Roadmap - development of a suitable vaccine with at least 75% durable efficacy against  
96 clinical malaria by 2030 (13).

97 CSP, which is pivotal in sporozoite development and invasion of hepatocytes, has long been  
98 considered as one of the leading pre-erythrocytic antigens for the development of a malaria  
99 vaccine. R21 has been designed and developed at the Jenner Institute, University of Oxford  
100 since 2012 (14). This is an improved RTS,S construct, containing recombinant particles  
101 expressing the central repeat and the C-terminus of the CSP fused to the Hepatitis B surface  
102 antigen (HBsAg). It does not contain the four-fold excess of unfused HBsAg protein present  
103 in RTS,S, which was required for particle formation(15). CSP comprises around 20% of the  
104 total protein content in RTS,S and a large proportion of the antibody response induced by  
105 RTS,S is towards the HBsAg (16). In contrast, R21 contains only fusion protein moieties, with  
106 no unfused HBsAg, which increases the density of CSP antigen on the virus-like particle  
107 (VLP). As a result, a 50µg dose of R21 contains about 25µg of CSP antigen compared with  
108 10µg of CSP in a standard adult 50µg dose of RTS,S. This was achieved by expressing R21 in  
109 an improved yeast expression system, *Pichia pastoris*, rather than in *Saccharomyces*  
110 *cerevisiae*. At the C-terminus of R21, a four amino acid sequence was added, EPEA (C-tag),  
111 for efficient immunochromatographic purification of R21. This sequence is found many  
112 times in the proteome of malaria parasites and humans but had not, to our knowledge,  
113 been used previously in any vaccine administered to humans (17).

114 In murine studies, R21 predominantly induced antibodies to CSP rather than HBsAg with  
115 comparable CSP immunogenicity and efficacy to RTS,S. Sporozoite challenge (1000  
116 sporozoites per mouse injected intravenously) using transgenic *P. berghei* parasites

117 (expressing the *Plasmodium falciparum* CSP homologue) performed in mice showed that  
118 R21 adjuvanted with Matrix-M™(MM) elicited 87.5 to 100% sterile protection (14).

119 Adjuvants can enhance the immunogenicity and efficacy of protein or VLP-based vaccines,  
120 and MM is an attractive relatively novel vaccine adjuvant for this purpose. As with other  
121 matrix formulations of *Quillaja* saponins, it shows acceptable safety in large numbers of  
122 recipients (18), and the ability to enhance both cellular and humoral immune responses to a  
123 range of antigens (19-24). In addition to the saponin, QS21, the AS01 adjuvant used with  
124 RTS,S also contains 50 µg of the immunostimulant, monophosphoryl lipid A (MPL). No such  
125 TLR4 ligand is present in the MM adjuvant which could lead to an improved safety profile  
126 and lower costs of manufacture. Therefore, we initially conducted a Phase I, first-in-human,  
127 open-label clinical trial to assess the safety and immunogenicity of R21 administered alone  
128 and with the novel saponin-based adjuvant, MM, in healthy UK volunteers. On the basis of  
129 an encouraging safety profile and comparable humoral immunogenicity to RTS,S/AS01<sub>B</sub>, but  
130 at the lower dose of 10µg, we tested this dose in Burkinabe adult volunteers and extended  
131 the UK study to assess the immunogenicity of an even lower dose of 2µg R21.

132

## 133 **METHODS**

### 134 **Study design and participants**

135 The Phase Ia study was conducted in healthy adults between the ages of 18 and 50 years at  
136 the Centre for Clinical Vaccinology and Tropical Medicine at the University of Oxford and the  
137 NIHR Imperial Clinical Research Facility, London in the United Kingdom.

138 Subsequently, the Phase Ib study was conducted in healthy Burkinabe adults aged between  
139 18 and 45 years at the Centre National de Recherche et Formation sur le Paludisme (CNRFP)  
140 research unit, Banfora in Burkina Faso. Details on trial site in Burkina are provided  
141 elsewhere (25). All participants provided written informed consent. The Phase Ia study was  
142 an observational, open-label, first-in-human clinical trial of R21 at a range of doses. Eligible  
143 participants were assigned to one of four groups and received three doses of R21 at either  
144 2µg, 10µg or 50µg administered alone or formulated with Matrix-M (Figure 1). The first  
145 three vaccinations in Groups 1-3 occurred in a staggered manner and interim safety reviews  
146 were conducted by the local safety monitor prior to progression to the higher dose group.  
147 The Phase Ib study was a single-blinded randomised, controlled trial assessing three doses  
148 of R21 10µg administered with MM in Burkinabe adults against a saline placebo (Figure 1).  
149 Despite single-blinding, investigators were unaware of group assignment throughout the  
150 study duration. The Phase 1b study only commenced after a satisfactory Data Safety and  
151 Monitoring Board (DSMB) review of the interim safety report for the 10µg and 50µg dose of  
152 R21 given to volunteers in the Phase Ia study. Volunteers were randomised to receive  
153 R21/MM or normal saline placebo. Full details regarding the study conduct are provided in  
154 the protocols for the two studies, which are available online (26, 27).

155 The Phase Ia study protocol and associated documents were reviewed and approved by the  
156 UK National Research Ethics Service, Committee South Central–Berkshire B (Ref:  
157 15/SC/0386), the Medicines and Healthcare Products Regulatory Agency (Ref:  
158 21584/0352/001-0001), and the Oxford University Clinical Trials and Research Governance  
159 team, who independently monitored compliance with Good Clinical Practice guidelines. The  
160 trial was registered with ClinicalTrials.gov (Ref: NCT02572388) and an independent local  
161 safety monitor provided safety oversight. The study protocol for the Phase Ib study was  
162 approved by the Burkina Faso regulatory authorities, The Burkina Faso Ministry of Health  
163 Ethical Committee for Biomedical Research (2014-10-118), the institutional review board of  
164 the Centre National de Recherche et de Formation sur le Paludisme (CIB/CNRFP), and  
165 Oxford Tropical Research Ethics Committee (OXTREC Reference: 36-15). The trial was  
166 registered with ClinicalTrials.gov (Ref: NCT02925403). An independent DSMB provided  
167 oversight and reviewed preliminary safety data before vaccinations commenced. The trial  
168 was monitored by an external organization (Margan Clinical Research Organization). Both  
169 studies were conducted according to the principles of the Declaration of Helsinki (2008) and  
170 the International Conference on Harmonization Good Clinical Practice guidelines.

## 171 **Procedures**

172 R21 was thawed to room temperature and administered intramuscularly into the deltoid  
173 muscle within 1 hour of removal from the freezer, either alone, or mixed with an adjuvant at  
174 the bedside, immediately prior to administration.

175 Volunteers were observed for 60 minutes following vaccine administration. In the Phase Ia  
176 study, follow-up visits were scheduled for days 1, 7, 14, 29, 35, 42, 57, 63, 70, 84 and 238,  
177 with an additional visit at day 3 post-vaccination for the first three volunteers in Groups 1-3.



178 All participants recorded their temperature and any solicited local and systemic adverse  
179 events for 7 days post-vaccination and unsolicited adverse events for 28 days post-  
180 vaccination using an electronic diary. A review of solicited and unsolicited adverse events  
181 (AEs) occurred at each follow-up visit. Safety bloods including full blood count, renal  
182 function and liver function tests were done on visits at day 0, 7, 28, 35, 56, 63, 84 and 238.  
183 In the Phase Ib study, volunteers were visited at home daily for 6 days after each vaccination  
184 by a field worker for assessment and recording of any solicited and unsolicited AEs in diary  
185 cards. They were also seen in clinic at day 7 and day 28 after each vaccination and attended  
186 a final follow up visit one year after enrolment. Safety bloods including full blood count,  
187 creatinine and alanine aminotransaminase were done in clinic at day 0, 7, 28, 35, 56, 63, 84,  
188 140 and 365. Severity grading of AEs and the assignment of a causal relationship for AEs  
189 were conducted according to predefined guidelines stated in the protocol, which were  
190 harmonised across both clinical trials for grading of solicited AEs. For unsolicited AEs,  
191 MedDRA (MedDRA® the Medical Dictionary for Regulatory Activities terminology) was used  
192 for coding in the UK clinical trial. In the Burkina trial, the DAIDS AE grading table was used  
193 (28).

194 Antibody responses measured by anti-NANP IgG ELISA were performed at all time points  
195 and IgG antibody avidity was assessed by sodium thiocyanate (NaSCN)-displacement ELISA.  
196 To assess whether antibodies to the C-tag used for R21 purification were induced by  
197 vaccination, N-terminal biotinylated peptides were constructed for the C-tag (EPEA), the C-  
198 tag plus the four adjacent amino acids in the R21 construct (WVYIEPEA) forming an 8-mer  
199 and the C-tag plus the eleven adjacent amino acids in the R21 construct (LPIFFCLWVYIEPEA)  
200 forming a 15-mer. For hepatitis B, antibodies to the HBsAg were measured using the Abbot

201 Architect 2000i chemiluminescent micro-particle immunoassay (CMIA). Antibody  
202 concentration of 100.0mIU/ml or greater was considered positive. Only groups 1, 2 and 3  
203 were assayed for C-tag antibodies. *Ex-vivo* IFN- $\gamma$  ELISpot responses to CSP were assessed on  
204 samples from day 0, 42 and 84, (ELISpots were not performed in the Burkinabe cohort as  
205 PBMC were not collected). Full details of the methods for all assays are provided in the  
206 supplementary appendix.

## 207 **Outcomes**

208 The primary objective was to assess the safety and tolerability of R21 with and without  
209 adjuvant MM in healthy UK and Burkinabe volunteers. The primary outcome measures  
210 included occurrence of solicited local and systemic reactogenicity signs and symptoms for 7  
211 days following the vaccination, occurrence of unsolicited AEs for 28 days following the  
212 vaccination, change from baseline for safety laboratory measures and occurrence of serious  
213 AEs during the whole study duration. The secondary objective was to assess the cellular and  
214 humoral immunogenicity of R21 with and without adjuvant MM in healthy UK volunteers  
215 and humoral immunogenicity in Burkinabe volunteers. The IgG response to the NANP repeat  
216 region was the primary immunogenicity readout, as this measure is associated with efficacy  
217 of RTS,S/AS01<sub>B</sub> (29).

## 218 **Statistical analysis**

219 Data were analysed using GraphPad Prism version 8.11 for Mac (GraphPad Software Inc.,  
220 California, USA) and Stata 10.0 (Statacorp LP, Texas, USA). Medians with interquartile ranges  
221 for each group are described. Kruskal-Wallis analysis and the Friedman test were used to  
222 compare peak immune responses with baseline. Significance testing of differences between

223 two groups used Mann-Whitney analysis. A Wilcoxon matched-pairs analysis was used to  
224 compare between time points within groups. A chi-squared test for trend was used to  
225 compare the safety data between different groups. A value of  $p < 0.05$  was considered  
226 statistically significant.

#### 227 **Role of the funding source**

228 The funders of the study had no role in study design, data collection, data analysis, data  
229 interpretation, or writing of the report. The authors (NV, KE, and AVSH) had full access to all  
230 the data in the study and were responsible for the decision to submit for publication.

231

232

233

234

235

236

237

## 238 RESULTS

### 239 Study Populations

240 The Phase 1a study in the UK was performed between the 1<sup>st</sup> October 2015 and 3<sup>rd</sup> January  
241 2017, and 31 of the 75 volunteers who were screened for eligibility were enrolled in the UK  
242 study. One volunteer in Group 1 withdrew after their first vaccination and was replaced.  
243 One Group 2 volunteer withdrew after their third vaccination. Two volunteers in Group 3  
244 withdrew after their first vaccination and were not replaced, at withdrawal there were no  
245 ongoing AEs and safety bloods were normal. All remaining volunteers completed follow-up.  
246 The Phase 1b study in Burkina Faso was performed from 26<sup>th</sup> August 2016 to 28<sup>th</sup> September  
247 2017. 13 of the 23 participants who were screened for eligibility were enrolled. Eight  
248 volunteers completed follow-up after receiving three doses of 10µg R21/MM in addition to  
249 four volunteers who received a saline placebo. One participant in the placebo group was  
250 lost to follow-up after the first dose and was replaced. Participant flow in the two clinical  
251 trials is summarised in Figure 1 and demographic data are summarised in Table 1.

	UK cohort (n=31)	Burkina Faso cohort (n=13)
<b>Sex</b>		
<b>Male</b>	15 (48%)	10 (77%)
<b>Female</b>	16 (52%)	3 (23%)
<b>Age (years)</b>	29.9 (8.3)	30.5 (8.1)

252

253 **Table 1. Baseline characteristics of enrolled volunteers.** Mean (SD) age for each cohort is  
254 shown.

### 255 Adverse events

256 No serious adverse reactions (SARs) or suspected unexpected serious adverse reactions  
257 (SUSARs) occurred. Two SAEs occurred; the first was deemed unlikely and the second not  
258 related to vaccination. Solicited local and systemic AEs in the first 7 days after each  
259 vaccination related to R21 vaccination in the UK population are shown in Figure 2 and in  
260 Supplementary Table 1. The majority of AEs reported were mild in severity and self-limiting.  
261 As expected, the addition of MM increased the reactogenicity of the 50µg dose compared  
262 with administration of 50µg of R21 alone. There was a significant trend for more  
263 reactogenicity in the higher dose groups than in the very low dose 2µg group ( $p < 0.0001$ ,  
264 Chi-squared test for trend across doses) where minimal reactogenicity was observed.  
265 Vaccine site pain was the most common local AE and was predominantly mild in severity.  
266 One volunteer in Group 1 reported a mild fever (37.7°C) and another volunteer in Group 1  
267 reported a moderate fever (38.1°C). Both occurred after the 2<sup>nd</sup> vaccination and resolved  
268 within 24 hours. One volunteer in Group 2 reported a fever of 39°C associated with a  
269 constellation of flu-like symptoms, eight days after their first vaccination, which resolved  
270 within 24 hours. Severe AEs were only reported in the 50µg R21/MM group by three  
271 volunteers and resolved within 48 hours.

272 Local and systemic AEs to 10µg R21 adjuvanted with MM in Burkinabe adults are shown in  
273 Figure 3. Very few solicited systemic AEs were reported and most local AEs were mild in  
274 nature with overall reactogenicity was significantly reduced compared to UK volunteers  
275 receiving the same dose, summarised in Table 2 and S2 ( $p < 0.0001$ , Chi-squared test). No  
276 volunteers reported severe AEs. Vaccine site pain was again the most commonly reported  
277 local AE. There were no episodes of fever associated with vaccination in the Burkinabe  
278 cohort. No solicited AEs were recorded in the saline placebo group.

279

	All AEs all vaccinations				
Location	UK	BF	UK	UK	UK
Vaccine/Adjuvant	R21/MM	R21/MM	RTS,S/AS01 <sub>B</sub>	R21/MM	R21 alone
Dose Vaccine	10µg	10µg	50µg	50µg	50µg
N enrolled	11	8	17	10	4
No. AEs					
Mild	94	5	166	65	19
Moderate	9	5	83	26	2
Severe	0	0	23	3	0
Total AEs	103	10	272	94	21
Chi-Squared (Pearson)	p<0.0001		p<0.0001		P=0.002*

280 **Table 2. Summary of adverse event (AE) frequency in UK and Burkina Faso (BF) cohorts immunised**  
 281 **with 10µg R21/MM and between two UK cohorts immunised with either 50µg R21/MM or 50µg**  
 282 **RTS,S/AS01<sub>B</sub> (data from (30)).** The total number of local and systemic AEs reported by all volunteers  
 283 following all vaccinations in each vaccine regime is shown (Pearson’s chi-squared test for trend). \*,  
 284 comparison with group immunized with 50µg R21/MM.

285

286 Furthermore, the reactogenicity profile observed in the 50µg R21/MM group is significantly  
 287 reduced ( $p < 0.0001$ , Pearson’s chi-squared test for trend) compared to that observed in a  
 288 previous clinical trial conducted in our institute using the same AE grading criteria, where  
 289 volunteers received three doses of 50µg RTS,S/AS01<sub>B</sub> given four weeks apart (30). This was  
 290 mainly due to a significant reduction in the number of systemic AEs reported with a higher  
 291 incidence of moderate and severe AEs reported by volunteers receiving RTS,S/AS01<sub>B</sub> (Table  
 292 2). In particular there were no post-vaccination fevers in the 50µg R21/MM group (0%  
 293 compared with 26% for 50µg RTS,S,  $p=0.004$  chi-squared test).

294 Unsolicited AEs collected for 28 days after each vaccination and those deemed possibly,  
 295 probably and definitely causally related to vaccination were predominantly mild in nature  
 296 for the UK trial (Table S3). Laboratory AEs were predominantly Grade 1 in the UK cohort and

297 are tabulated in Table S4. In the Burkinabe cohort, all unsolicited AEs were deemed unlikely  
298 or unrelated to vaccination (Table S5). A higher frequency of laboratory AEs were observed  
299 in the Burkinabe cohort in both the R21/MM and saline placebo vaccinated groups (Table  
300 S6).

### 301 **Immunogenicity**

#### 302 **Humoral responses**

303 IgG antibody titres to the NANP repeat region of the CSP antigen were measured by ELISA in  
304 the same laboratory by the same operator for both trials. In the UK cohort, addition of the  
305 Matrix-M adjuvant markedly increased antibody levels compared with R21 administered  
306 alone. Increasing titres of NANP-specific IgG were detected with increasing doses of R21  
307 after the first and second vaccinations, however there was no significant difference  
308 between dose groups after the third immunisation (Kruskal-Wallis analyses,  $p=0.02$ ,  $p=0.04$   
309 and  $p=0.12$  at D28, D56 and D84, respectively, Figure 4A and C). At day 238, titres were  
310 higher in the 10 $\mu$ g dose group than in the 50 $\mu$ g and 2 $\mu$ g groups (Kruskal-Wallis test with  
311 Dunn's multiple comparison test,  $p=0.06$ , Figure 4A and C).

312 Based on the quantity of CSP contained in each vaccine, the 10 $\mu$ g dose of R21 is most similar  
313 to the standard 50 $\mu$ g dose of RTS,S. IgG titres were compared to those in UK participants  
314 receiving three 50 $\mu$ g doses of RTS,S in previous UK clinical trials at the Jenner Institute.  
315 ELISA assays were run using the same protocol in the same laboratory by the same  
316 operator. There was no evidence of a difference between the peak IgG response to three  
317 10 $\mu$ g doses of R21 in MM to those induced by three 50 $\mu$ g doses of RTS,S/ AS01<sub>B</sub> (Mann-  
318 Whitney test,  $p=0.5$ , Figure 4B) (30, 31). Avidity of IgG antibodies at the peak of the immune

319 response did not vary between either dose of R21 in MM or compared to vaccination with  
320 RTS,S (Kruskal-Wallis test,  $p=0.6$ , Figure 4D).

321 In the Burkinabe cohort, pre-vaccination titres to CSP were higher than in UK participants  
322 due to malaria exposure. Responses to vaccination did not differ significantly between the  
323 two cohorts after the first two vaccinations, however the third dose of R21 failed to boost  
324 responses in the Burkinabe cohort, and as a consequence, titres were significantly lower at  
325 D84, four weeks after the third dose (Mann-Whitney test,  $p=0.02$ , Figure 4E) compared to  
326 UK vaccinees. By D140, responses in the Burkinabe R21/MM cohort had increased  
327 significantly from D84 (Wilcoxon matched-pairs 2-tailed,  $p=0.008$ ), and were significantly  
328 higher than those in the placebo group at D140 and D365 (Mann-Whitney test,  $p=0.004$   
329 D140,  $p=0.04$  D365). Although titres were lower at D84 in the Burkinabe cohort than the UK,  
330 antibody avidity was significantly higher (Mann-Whitney test,  $p=0.001$ , Figure 4F). The  
331 avidity of the antibody response also increased significantly after vaccination in the  
332 Burkinabe cohort (Mann-Whitney test,  $p=0.008$ ). The induction by R21/MM of high avidity  
333 antibodies, and initial evidence of boosting through natural malaria exposure in Burkinabe  
334 adults, with antibody titres comparable to those observed in UK vaccinees at D365, is  
335 interesting, particularly as it has been difficult to detect evidence of significant immune  
336 boosting by natural malaria exposure in RTS,S/AS01<sub>B</sub> vaccinees in malaria-exposed or semi-  
337 immune adults (32, 33).

338 The functional activity of CSP-specific antibodies was assessed *in vitro* by measuring blocking  
339 of sporozoite invasion into a human hepatoma cell line in the presence of serum from  
340 vaccinees (inhibition of sporozoite invasion, ISI assay). Prior to vaccination, serum from UK  
341 participants did not demonstrate ISI activity, while serum from Burkinabe volunteers



342 demonstrated up to 50% inhibition ( $p=0.02$ , Mann-Whitney, Figure 5A). Vaccination with  
343 R21/MM significantly increased the ISI activity from baseline to D84 in the UK cohort  
344 ( $p=0.03$ , Wilcoxon matched-pairs) and there was a trend towards higher ISI activity in the  
345 Burkinabe participants at D84 than in the UK participants ( $p=0.06$ , Mann-Whitney). An  
346 association was detected between antibody titre and ISI activity in the Burkinabe cohort  
347 ( $r=0.81$ ,  $p=0.07$ , Spearman's rank test, Figure 5B), but not in the UK cohort.

348 Between 40% and 50% of participants in each UK group were seropositive to HBsAg prior to  
349 R21 vaccination, presumably due to previous vaccination against Hepatitis B. Of those that  
350 were seronegative at vaccination, 0, 17% and 50% of volunteers seroconverted for HBsAg  
351 after 3 doses of R21/MM in the 2 $\mu$ g, 10 $\mu$ g and 50 $\mu$ g dose groups, respectively. This is in  
352 contrast to vaccination with 3 doses of RTS,S/AS01<sub>B</sub> which induced seroconversion in 100%  
353 of seronegative vaccinees in a Belgian study (34) (Figure 5C). In the Burkinabe cohort,  
354 seroconversion was detected in only 1 of 7 (17%) volunteers that were seronegative prior to  
355 vaccination.

356 A four amino acid label (EPEA) was added to the C-terminal of the R21 construct (C-tag) to  
357 facilitate protein purification during biomanufacture. Antibody response to the C-tag was  
358 assessed by ELISA in the UK cohort only. C-tag IgG responses were not induced by  
359 vaccination with R21, although one participant had a very weak response to EPEA pre-  
360 vaccination, which was not detected post-vaccination at Day 84 (Figure 5D).

### 361 **Cell-mediated immunity**

362 T cell responses to CSP were enumerated by *ex vivo* IFN- $\gamma$  ELISpot and were weak in  
363 R21/MM vaccinees (Figure 5E) and undetectable in the unadjuvanted group. The magnitude

364 of responses were comparable to those observed in recipients of RTS,S/AS01<sub>B</sub> (35).  
365 Responses peaked at day 42, two weeks after the second dose and there were no significant  
366 differences between groups (Figure 5F).

367

## 368 **DISCUSSION**

369 We report here the safety and immunogenicity of the first-in-human administration of the  
370 novel malaria vaccine candidate, R21, administered with the saponin-based adjuvant, MM  
371 in UK and African adults. This vaccination approach was safe and very well tolerated with  
372 very low doses inducing high antibody levels, comparable to those previously associated  
373 with protection in humans induced by other malaria anti-sporozoite vaccines. The  
374 reactogenicity profile of 50µg R21/MM was significantly improved compared to the  
375 standard adult 50µg RTS,S/AS01<sub>B</sub> dose in healthy adult UK volunteers (30) and importantly,  
376 post-vaccination fever was not detected. An effective vaccine will be an essential tool in the  
377 malaria elimination and eradication efforts and the absence of fever is a significant benefit  
378 in the context of mass administration campaigns. Minimal reactogenicity was detected in  
379 African adults and this was significantly reduced compared to UK adults at a dose of 10µg  
380 R21/MM.

381 Humoral responses observed to the conserved central NANP repeat region are comparable  
382 to previous RTS,S/AS01<sub>B</sub> data from two clinical trials conducted in the UK where the same  
383 ELISA was used. The humoral response is predominantly responsible for the efficacy of  
384 RTS,S/AS01<sub>B</sub> against malaria infection (36). It is therefore encouraging that comparable  
385 humoral responses are elicited at 28 days after the third vaccination even at the very low

386 dose of 2µg and 10µg. This could have significant dose-sparing and cost-saving implications  
387 for vaccine production.

388 R21/MM administered at doses of 10µg and 50µg did not result in significant boosting of  
389 the humoral response after the third vaccination compared to the peak response after the  
390 second vaccination. Though RTS,S is currently generally given in a three dose schedule,  
391 administered 4 weeks apart, preliminary studies with RTS,S assessed regimens where the  
392 third dose was delayed to 24-28 weeks (15, 37). Though these studies did not show  
393 significant boosting of the humoral response with a delayed third dose, higher level efficacy  
394 of 86% was observed in malaria-naïve adults who received RTS,S/AS02 given at 0, 1 and 7  
395 months (37). However, these volunteers had also received one-fifth of the vaccine and  
396 adjuvant at the third administration due to earlier reactogenicity concerns. Studies in  
397 African adults living in malaria endemic regions have shown that there is boosting of the  
398 immune response after the third dose with a 0, 1 and 6 month schedule (38, 39). More  
399 recently, Regules et al. revisited a delayed fractional (i.e. one fifth) dose with RTS,S/AS01<sub>B</sub>  
400 where high level efficacy was again observed. This was associated with increased somatic  
401 hypermutation and antibody avidity, rather than the magnitude of the humoral response  
402 (40).

403 Durable antibody responses were observed at 6 months after the final vaccination. The  
404 10µg dose elicited significantly higher titres compared with the 50µg dose at 6 months.  
405 Though RTS,S/AS01<sub>B</sub> demonstrated short-term efficacy in malaria-naïve and endemic  
406 populations, durable protective immunity is a hitherto unmet goal. It is well recognised that  
407 the antibody responses to the CSP elicited by RTS,S/AS01<sub>B</sub> decay over time, which is  
408 reflected in reduced vaccine efficacy (33, 41, 42). That a lower dose of protein should induce

409 a more durable response is of particular interest from an immunological perspective. In  
410 other settings, higher priming antigen doses favour production of antigen-specific plasma  
411 cells that only have a short lifespan, whereas lower doses can preferentially drive the  
412 induction of immune memory (43, 44). A few of these plasma cells differentiate into long-  
413 lived plasma cells (LLPC) and in the absence of subsequent antigen exposure; the proportion  
414 of LLPC generated by a vaccine is predictive of the durability of the antibody response (45).  
415 Antibody titres at 6-12 months after immunisation would reflect this as the initial short-  
416 term plasma cell response would decline.

417 A successful malaria vaccine is needed to help reduce malaria morbidity and mortality in  
418 over 30 million children born in malaria endemic regions of Africa each year, as well as for  
419 disease control and eventual eradication efforts in other continents. For a four-dose  
420 regimen, such as that under evaluation by MVIP, this would require at least 130 million  
421 doses per annum for infants in Africa alone. The finding that R21 can induce comparable  
422 immune responses to RTS,S using just a fifth to a 25<sup>th</sup> of the dose used by the RTS,S suggests  
423 that substantial dose sparing should be possible reducing cost of goods and easing the  
424 challenge of making hundreds of millions of doses of vaccine each year. The initial improved  
425 safety profile of R21 observed with the Matrix-M adjuvant compared to the standard  
426 RTS,S/AS01<sub>B</sub> regimen, along with good durability of immune response after the low dose  
427 R21/MM is also encouraging. Furthermore, R21 is now being manufactured by the Serum  
428 Institute of India, who are the world's largest vaccine supplier by volume and supply 40% of  
429 the vaccines funded by GAVI (46), increasing the potential to manufacture R21/MM on the  
430 scale likely to be required for effective malaria control and eventual elimination.

431 In conclusion, these Phase I clinical trials showed that the novel malaria vaccine candidate,

432 R21 adjuvanted with Matrix-M was safe and well tolerated in both UK and African subjects.

433 Phase IIa studies to assess efficacy in an established malaria sporozoite challenge model are

434 currently ongoing.

435 **ACKNOWLEDGEMENTS:**

436 We thank the members of the Data Safety Monitoring Board and all the study volunteers.  
437 The UK study was funded by the National Institute for Health Research (NIHR) Oxford  
438 Biomedical Research Centre (BRC). The views expressed are those of the authors and not  
439 necessarily those of the NHS, the NIHR or the Department of Health. Vaccine manufacture  
440 was funded by the UK Medical Research Council (Grant no: MR/J008680/1) and the  
441 European Commission FP7 programme (Grant no: 305282). The study in Burkina Faso was  
442 supported by a Strategic Primer grant award from the European and Developing Countries  
443 Clinical Trials Partnership (EDCTP) with co-funding from Swedish International Development  
444 Cooperation Agency (Sida); UK Medical Research Council; Irish Aid, Department of Foreign  
445 Affairs and Trade, Ireland; and Bundesministerium für Bildung und Forschung (BMBF),  
446 Germany. It was performed as part of the work programme of the EDCTP Malaria Vectored  
447 Vaccines Consortium 2 (MVVC2), (grant number SP.2011.41304.025). The European Vaccine  
448 Initiative (EVI) coordinated the EDCTP-funded MVVC project. Odile Leroy was executive  
449 director of EVI at the time of the study. N.K.V. is an employee of EVI. The work was also  
450 supported by the UK National Institute of Health Research through the Oxford Biomedical  
451 Research Centre (<http://oxfordbrc.nihr.ac.uk/>) (A91301 Adult Vaccine) and the Wellcome  
452 Trust (<https://www.wellcome.ac.uk/>) (084113/Z/07/Z). We are grateful to Shahid Khan and  
453 Chris Janse at LUMC for provision of transgenic parasite lines and to Alexandra Spencer,  
454 Ahmed Salman and Marta Ulaszewska for immunopotency assays and preparation of  
455 infected mosquitoes. We thank Philip Angell-Manning for his contribution to R21  
456 manufacturing. We are also grateful to Ruth Payne and Saranya Sridhar for contributing to  
457 clinical care of participants and to Catherine Mair and Kate Harrison for assistance with

458 sample processing. We thank Nicola Williams of the Nuffield Department of Primary Health  
459 Care Sciences at the University of Oxford for statistical review of the manuscript.

460

#### 461 **Declaration of interests**

462 KAC, NaV, SCG, KJE and AVSH are named as co-inventors or contributors on patent filings  
463 related to the R21 vaccine candidate. All are or were University of Oxford students and / or  
464 employees.

465

466

467

468

469

470

471

#### 472 **REFERENCES**

473

474 1. WHO. World Malaria Report2018; (19 November 2018). Available from:  
475 <http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/>.

476 2. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect  
477 of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. *Nature*.  
478 2015;526(7572):207-11.

479 3. WHO. WHO Policy Recommendation: Seasonal Malaria Chemoprevention (SMC)  
480 for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel  
481 sub-region in Africa. Geneva: WHO; 2012.

482 4. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin  
483 resistance in Plasmodium falciparum malaria. *N Engl J Med*. 2009;361(5):455-67.

484 5. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of  
485 artemisinin resistance in Plasmodium falciparum malaria. *N Engl J Med*. 2014;371(5):411-  
486 23.


487 6. Hemingway J, Ranson H, Magill A, Kolaczinski J, Fornadel C, Gimnig J, et al.  
488 Averting a malaria disaster: will insecticide resistance derail malaria control? *Lancet*.  
489 2016;387(10029):1785-8.

- 490 7. Rts SCTP. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months  
491 after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11  
492 African sites. *PLoS Med.* 2014;11(7):e1001685.
- 493 8. Rts SCTP. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a  
494 booster dose in infants and children in Africa: final results of a phase 3, individually  
495 randomised, controlled trial. *Lancet.* 2015;386(9988):31-45.
- 496 9. Rts SCTP, Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, et al. A  
497 phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. *N Engl J Med.*  
498 2012;367(24):2284-95.
- 499 10. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann  
500 C, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. *N*  
501 *Engl J Med.* 2011;365(20):1863-75.
- 502 11. World Health O. Malaria vaccine: WHO position paper, January 2016 -  
503 Recommendations. *Vaccine.* 2017.
- 504 12. WHO. First malaria vaccine in Africa: A potential new tool for child health and  
505 improved malaria control. Geneva: WHO; April 2018.
- 506 13. Malaria Vaccine Funders Group. Malaria Vaccine Technology Roadmap 2013  
507 [Available from:  
508 [http://www.who.int/immunization/topics/malaria/vaccine\\_roadmap/TRM\\_update\\_nov13.pdf?](http://www.who.int/immunization/topics/malaria/vaccine_roadmap/TRM_update_nov13.pdf?ua=1)  
509 [ua=1](http://www.who.int/immunization/topics/malaria/vaccine_roadmap/TRM_update_nov13.pdf?ua=1).
- 510 14. Collins KA, Snaith R, Cottingham MG, Gilbert SC, Hill AVS. Enhancing protective  
511 immunity to malaria with a highly immunogenic virus-like particle vaccine. *Scientific*  
512 *reports.* 2017;7:46621.
- 513 15. Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, LaChance R, et al.  
514 Safety, immunogenicity, and efficacy of a recombinantly produced *Plasmodium falciparum*  
515 circumsporozoite protein-hepatitis B surface antigen subunit vaccine. *J Infect Dis.*  
516 1995;171(6):1576-85.
- 517 16. Aide P, Dobano C, Sacarlal J, Aponte JJ, Mandomando I, Guinovart C, et al. Four  
518 year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during  
519 a phase IIb trial. *Vaccine.* 2011;29(35):6059-67.
- 520 17. Jin J, Simmons G. Inhibitory Antibodies Targeting Emerging Viruses: Advancements  
521 and Mechanisms. *Clin Vaccine Immunol.* 2016;23(7):535-9.
- 522 18. Bigaeva E, Doorn E, Liu H, Hak E. Meta-Analysis on Randomized Controlled Trials  
523 of Vaccines with QS-21 or ISCOMATRIX Adjuvant: Safety and Tolerability. *PLoS One.*  
524 2016;11(5):e0154757.
- 525 19. Bengtsson KL, Karlsson KH, Magnusson SE, Reimer JM, Stertman L. Matrix-M  
526 adjuvant: enhancing immune responses by 'setting the stage' for the antigen. *Expert Rev*  
527 *Vaccines.* 2013;12(8):821-3.
- 528 20. Cox RJ, Pedersen G, Madhun AS, Svindland S, Saevik M, Breakwell L, et al.  
529 Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I  
530 clinical trial. *Vaccine.* 2011;29(45):8049-59.
- 531 21. Cox RJ, Major D, Pedersen G, Pathirana RD, Hoschler K, Guilfoyle K, et al. Matrix  
532 M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized  
533 Clinical Trial and Provides Protection from Highly Pathogenic Influenza Challenge in  
534 Ferrets. *PLoS One.* 2015;10(7):e0131652.
- 535 22. Bengtsson KL, Song H, Stertman L, Liu Y, Flyer DC, Massare MJ, et al. Matrix-M  
536 adjuvant enhances antibody, cellular and protective immune responses of a Zaire  
537 Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. *Vaccine.*  
538 2016;34(16):1927-35.




- 539 23. Cox F, Saeland E, Baart M, Koldijk M, Tolboom J, Dekking L, et al. Matrix-M  
540 adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine.  
541 *Virology*. 2015;12:210.
- 542 24. de Cassan SC, Forbes EK, Douglas AD, Milicic A, Singh B, Gupta P, et al. The  
543 requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of  
544 protein vaccines can be overcome by prior immunization with a recombinant adenovirus.  
545 *Journal of Immunology*. 2011;187(5):2602-16.
- 546 25. Tiono AB, Nebie I, Anagnostou N, Coulibaly AS, Bowyer G, Lam E, et al. First field  
547 efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17  
548 months old infants and children. *PLoS One*. 2018;13(12):e0208328.
- 549 26. Hill A. Clinical Trial Protocol: VAC053 Protocol v5.0. VAC 053: Safety and  
550 immunogenicity of a protein particle malaria vaccine candidate, R21, administered with and  
551 without Matrix-M1 in healthy UK volunteers: University of Oxford; 2019.
- 552 27. Hill A. Clinical Trial Protocol: VAC060 Protocol v3.0. VAC 060: A Phase Ib  
553 randomised, controlled, single-blind study to assess the safety, immunogenicity of the  
554 Malaria Vaccine Candidate R21 with Matrix-M1 adjuvant in West African adult volunteers:  
555 University of Oxford; 2019.
- 556 28. U.S. Department of Health and Human Services NIOH, National Institute of Allergy  
557 and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the  
558 Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. USA; 2017.
- 559 29. White MT, Verity R, Griffin JT, Asante KP, Owusu-Agyei S, Greenwood B, et al.  
560 Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine  
561 efficacy: secondary analysis of data from a phase 3 randomised controlled trial. *Lancet Infect  
562 Dis*. 2015;15(12):1450-8.
- 563 30. Rampling T, Ewer KJ, Bowyer G, Bliss CM, Edwards NJ, Wright D, et al. Safety and  
564 High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B with  
565 ChAd-MVA Vectored Vaccines Expressing ME-TRAP. *J Infect Dis*. 2016.
- 566 31. Rampling T, Ewer KJ, Bowyer G, Edwards NJ, Wright D, Sridhar S, et al. Safety and  
567 efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant  
568 ChAd63-MVA-vectored vaccines expressing ME-TRAP. *NPJ Vaccines*. 2018;3:49.
- 569 32. Polhemus ME, Remich SA, Ogutu BR, Waitumbi JN, Otieno L, Apollo S, et al.  
570 Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.  
571 *PLoS One*. 2009;4(7):e6465.
- 572 33. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, et al.  
573 Efficacy of RTS,S/AS02 malaria vaccine against *Plasmodium falciparum* infection in semi-  
574 immune adult men in The Gambia: a randomised trial. *Lancet*. 2001;358(9297):1927-34.
- 575 34. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, et  
576 al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B  
577 and RTS,S/AS02A in malaria-naïve adults: safety, efficacy, and immunologic associates of  
578 protection. *The Journal of Infectious Diseases*. 2009;200(3):337-46.
- 579 35. Ockenhouse CF, Regules J, Tosh D, Cowden J, Kathcart A, Cummings J, et al.  
580 Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite  
581 Challenge in Healthy Malaria-Naïve Adults. *PLoS One*. 2015;10(7):e0131571.
- 582 36. White MT, Bejon P, Olotu A, Griffin JT, Riley EM, Kester KE, et al. The relationship  
583 between RTS,S vaccine-induced antibodies, CD4(+) T cell responses and protection against  
584 *Plasmodium falciparum* infection. *PLoS One*. 2013;8(4):e61395.
- 585 37. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A  
586 preliminary evaluation of a recombinant circumsporozoite protein vaccine against  
587 *Plasmodium falciparum* malaria. RTS,S Malaria Vaccine Evaluation Group. *N Engl J Med*.  
588 1997;336(2):86-91.


- 589 38. Doherty JF, Pinder M, Tornieporth N, Carton C, Vigneron L, Milligan P, et al. A  
590 phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in  
591 semi-immune adults in The Gambia. *Am J Trop Med Hyg.* 1999;61(6):865-8.
- 592 39. Stoute JA, Heppner DG, Jr., Mason CJ, Siangla J, Opollo MO, Kester KE, et al. Phase  
593 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a  
594 hyperendemic region of western Kenya. *Am J Trop Med Hyg.* 2006;75(1):166-70.
- 595 40. Regules JA, Cicatelli SB, Bennett JW, Paolino KM, Twomey PS, Moon JE, et al.  
596 Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a  
597 Controlled Human Malaria Parasite Infection and Immunogenicity Study. *J Infect Dis.*  
598 2016;214(5):762-71.
- 599 41. Olotu A, Fegan G, Wambua J, Nyangweso G, Awuondo KO, Leach A, et al. Four-  
600 year efficacy of RTS,S/AS01E and its interaction with malaria exposure. *N Engl J Med.*  
601 2013;368(12):1111-20.
- 602 42. Stoute JA, Kester KE, Krzych U, Welde BT, Hall T, White K, et al. Long-term  
603 efficacy and immune responses following immunization with the RTS,S malaria vaccine. *J*  
604 *Infect Dis.* 1998;178(4):1139-44.
- 605 43. Ahman H, Kayhty H, Vuorela A, Leroy O, Eskola J. Dose dependency of antibody  
606 response in infants and children to pneumococcal polysaccharides conjugated to tetanus  
607 toxoid. *Vaccine.* 1999;17(20-21):2726-32.
- 608 44. Borrow R, Goldblatt D, Finn A, Southern J, Ashton L, Andrews N, et al.  
609 Immunogenicity of, and immunologic memory to, a reduced primary schedule of  
610 meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom. *Infect*  
611 *Immun.* 2003;71(10):5549-55.
- 612 45. Lightman SM, Utley A, Lee KP. Survival of Long-Lived Plasma Cells (LLPC):  
613 Piecing Together the Puzzle. *Frontiers in immunology.* 2019;10:965.
- 614 46. GAVI. Serum Founder wins inaugural 'Vaccine Hero' award  
615 2018 [Available from: [https://www.gavi.org/library/news/press-releases/2018/serum-](https://www.gavi.org/library/news/press-releases/2018/serum-founder-wins-inaugural-vaccine-hero-award/)  
616 [founder-wins-inaugural-vaccine-hero-award/](https://www.gavi.org/library/news/press-releases/2018/serum-founder-wins-inaugural-vaccine-hero-award/).  
617  
618




**Figure 1. Flow chart of study design and volunteer recruitment.** Abbreviations: BF, Burkina Faso; MM, Matrix-M; UK, United Kingdom. A total of 75 volunteers were screened and 31 were enrolled in total in the UK trial. One Group 1 volunteer withdrew consent after their first vaccination and was subsequently replaced. One Group 2 volunteer withdrew after their third vaccination and two Group 3 volunteers withdrew after their first vaccination and were not replaced. A total of 25 volunteers completed the UK study. A total of 23 volunteers were screened and 13 volunteers were enrolled in total in the BF trial. One volunteer in the placebo group was lost to follow up after the first dose and was replaced.



**Figure 2. Local (A, C, E) and systemic (B, D, F) solicited adverse events (AEs) reported by UK volunteers in the electronic diary card during the first seven days related to each vaccination given 4 weeks apart. R21 was either administered alone (n=4) or mixed with Matrix-M at different doses of 2µg (n=6), 10µg (n=10) and 50µg (n=8). Only the highest intensity of each AE per subject is listed. Data are combined for all AEs for all volunteers receiving the same vaccine at the stated time point.**




**Figure 3. Local and systemic solicited adverse events (AE) reported by Burkinabe volunteers (n=8) during the first seven days related to vaccination with a dose of 10 $\mu$ g R21/MM. Only the highest intensity of each AE per subject is shown. Data are combined for all AEs for all volunteers receiving the same vaccine at the stated time point. No solicited AEs were observed in the saline placebo group.**



**Figure 4. Antibody responses to R21/MM.** A) Median NANP IgG time courses in UK adults vaccinated with 10µg R21/MM (G1, circles, n=10), 50µg unadjuvanted R21 (G2, squares, n=3) or 50µg R21/MM (G3, triangles, n=8). B) Peak NANP IgG titres (D77-D84) in 10µg R21/MM group and in groups from two previous trials that were vaccinated with three doses of 50µg RTS,S/AS01B, Mann-Whitney p=0.48 (1, 2). C) Individual NANP IgG responses

at peak (D84) and D238 in UK adults by dose and a long-term follow-up visit (LTFU) between 22 and 35 months after first vaccination. Mann-Whitney analyses between groups at D84  $p=0.20$  and D238 ( $p=0.02$ ). Bars represent medians + interquartile ranges, IQRs. D) Avidity of NANP-specific IgG at peak (D84) in 10 and 50 $\mu$ g R21/MM groups and 50 $\mu$ g RTS,S/AS01<sub>B</sub> from two previous trials as in Figure 4B, Kruskal-Wallis  $p=0.08$ . E) NANP IgG time courses (median + IQRs) in UK adults in G1 (10 $\mu$ g R21/MM, circles) and Burkina Faso adults given the same dose of R21/MM (squares) or placebo (triangles). Titres at each time point were compared by Mann-Whitney analysis: D28  $p=0.75$ , D56  $p=0.12$ , D84  $p=0.02$  (UK vs. Burkina Faso, R21/MM). Between D84 and D140, titres increased significantly in the Burkina Faso cohort (Wilcoxon matched-pairs 2-tailed,  $p=0.008$ ) and at both D140 and D365, titres in the R21/MM group remained significantly higher than in the placebo control group (Mann-Whitney test,  $p=0.004$  D140,  $p=0.04$  D365). F) Antibody avidity at baseline and peak immune response (D84) in 10 $\mu$ g R21/MM groups (Mann-Whitney,  $p=0.008$  for BF D0 comparison with D84,  $p=0.001$  for D84 comparison between UK and BF).



**Figure 5. Extended R21/MM immunology.** A) Percentage of infection blocked in the inhibition of sporozoite invasion assay (ISI) at baseline and D84 in a subset of UK and Burkinabe adults vaccinated with 10 $\mu$ g R21/MM and Burkinabe adults vaccinated with saline (controls). Wilcoxon matched-pairs analyses for change over baseline and 2-tailed



Mann-Whitney for comparisons between groups). B) Association between D84 NANP IgG titres and the percentage of infection blocked in UK and Burkinabe adults vaccinated with 10µg R21/MM. Spearman rank analyses. C) Hepatitis B surface antigen antibody responses in each group before and after vaccination. D) ELISA responses to C-tag peptides at day 0 (pre-vaccination) and Day 84 (4 weeks post-vaccination). Line shows cut-off for positivity, determined as the mean responses at day 0 plus three standard deviations. E) Median CSP-specific T cell responses as measured by IFN $\gamma$  ELISpot. F) individual CSP-specific T cell responses for each group at the peak time point (day 42).

1. Rampling T, Ewer KJ, Bowyer G, Bliss CM, Edwards NJ, Wright D, et al. Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B with ChAd-MVA Vectored Vaccines Expressing ME-TRAP. *J Infect Dis*. 2016.
2. Rampling T, Ewer KJ, Bowyer G, Edwards NJ, Wright D, Sridhar S, et al. Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. *NPJ Vaccines*. 2018;3:49.